Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3103954#aggregation> ?p ?o. }
Showing items 1 to 33 of
33
with 100 items per page.
- aggregation classification "C3".
- aggregation creator B127256.
- aggregation creator B127257.
- aggregation creator B127258.
- aggregation creator B127259.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation hasFormat 3103954.bibtex.
- aggregation hasFormat 3103954.csv.
- aggregation hasFormat 3103954.dc.
- aggregation hasFormat 3103954.didl.
- aggregation hasFormat 3103954.doc.
- aggregation hasFormat 3103954.json.
- aggregation hasFormat 3103954.mets.
- aggregation hasFormat 3103954.mods.
- aggregation hasFormat 3103954.rdf.
- aggregation hasFormat 3103954.ris.
- aggregation hasFormat 3103954.txt.
- aggregation hasFormat 3103954.xls.
- aggregation hasFormat 3103954.yaml.
- aggregation isPartOf urn:issn:0001-5644.
- aggregation language "eng".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Cisplatin-modified de Gramont in second line therapy for pancreatic adenocarcinoma".
- aggregation abstract "Introduction : Today there is growing evidence supporting the benefit of 2nd line chemotherapy after gemcitabine failure in pancreatic cancer. However, which type of chemotherapy is preferred has not been defined yet. Different therapeutic regimens have been tested in small trials and have shown a limited significant clinical benefit. In Belgium, combination chemotherapy of cisplatin and 5-fluorouracil (5FU) + leucovorin according to the modified de Gramont schedule is the treatment of choice. Combination therapy with cisplatinum and 5FU has yielded positive results in 3 trials. Aim : We analyzed retrospectively the data in two Belgian centres in a non-selected population. Methods : Between January 2004 and October 2011, 48 patients with histologically proven recurrent, or unresectable pancreatic adenocarcinoma who had received cisplatin and 5FU - leucovorin (modified de Gramont) as 2nd line therapy were identified. We retrospectively analyzed the following parameters : progression free survival and overall survival for each line (after the start of 1st and 2nd line). We also assessed the efficacy of the 2nd line regimen by the growth modulation index or progression free survival ratio. Results : The median progression free survival after the start of 1st line was 5,4 months (95% CI 4,1 - 6,6). The median progression free survival after the start of 2nd line was 3,6 months (95% CI 1,8-5,5). More interestingly, the median overall survival after the start of 1st line was 12 months (95% CI 9,4-14,6). The 2- and 1-year survival rate after the start of 1st line therapy were 8% (4/48) and 50% (24/48), respectively. Twenty three percent of patients had a growth modulation index > 1,33, referring to a benefit in progression free survival of 2nd line therapy that was greater than that of treatment in 1st line. Conclusions : We show an overall survival close to 12 months with cisplatinum-5FU in 2nd line therapy in a retrospective analysis, an overall survival that is higher than what has been described before. This good result was not due to selection of a patient population that responds well to chemotherapy, since 23% of patients showed a longer progression free survival in 2nd line than in 1st line. These results are in agreement with what is found in the literature : both combination therapy with oxaliplatin and cisplatin show promising results in pancreatic cancer. Oxaliplatin may be preferred because of its lower toxicity, but a recent meta-analysis shows more efficacy for cisplatin. Sequential therapy with good overall survival and good quality of life may be preferred to strong upfront therapy in an incurable disease such as pancreatic cancer.".
- aggregation authorList BK327044.
- aggregation issue "1".
- aggregation volume "75".
- aggregation isDescribedBy 3103954.
- aggregation similarTo LU-3103954.